Brookline Capital Management Weighs in on MNPR Q1 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Investment analysts at Brookline Capital Management issued their Q1 2025 EPS estimates for shares of Monopar Therapeutics in a research report issued to clients and investors on Monday, January 6th. Brookline Capital Management analyst K. Dolliver forecasts that the company will earn ($0.78) per share for the quarter. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. Brookline Capital Management also issued estimates for Monopar Therapeutics’ Q2 2025 earnings at ($0.93) EPS, Q3 2025 earnings at ($1.17) EPS, Q4 2025 earnings at ($1.27) EPS and FY2025 earnings at ($4.07) EPS.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09.

A number of other equities research analysts have also recently commented on the stock. HC Wainwright increased their price objective on shares of Monopar Therapeutics from $6.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, November 11th. Piper Sandler initiated coverage on shares of Monopar Therapeutics in a research note on Friday. They issued an “overweight” rating and a $72.00 price objective on the stock. Finally, Rodman & Renshaw initiated coverage on shares of Monopar Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $50.00 price target on the stock.

Monopar Therapeutics Trading Up 3.6 %

Shares of NASDAQ MNPR opened at $25.35 on Thursday. The stock has a market cap of $133.80 million, a price-to-earnings ratio of -12.87 and a beta of 1.23. Monopar Therapeutics has a 52 week low of $1.54 and a 52 week high of $38.50. The company’s 50-day moving average price is $21.84 and its 200 day moving average price is $10.70.

Insider Transactions at Monopar Therapeutics

In other Monopar Therapeutics news, CFO Karthik Radhakrishnan purchased 1,550 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The shares were purchased at an average price of $16.25 per share, for a total transaction of $25,187.50. Following the completion of the acquisition, the chief financial officer now owns 1,550 shares of the company’s stock, valued at approximately $25,187.50. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 34.90% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.